Healios KKHLOSF 57 Return-on-Tangible-Equity is -769.83% as of Mar. 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.41 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,196 Biotechnology companies, Healios KK ranks worse than 83611.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Healios KK's annualized net income for the quarter that ended in Mar. 2026 was $-87.67 Mil. Healios KK's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $11.39 Mil. Therefore, Healios KK's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -769.83%.
The historical rank and industry rank for Healios KK's Return-on-Tangible-Equity or its related term are showing as below:
HLOSF's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.19 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Healios KK (OTCPK:HLOSF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Healios KK Return-on-Tangible-Equity Related Terms
Healios KK Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Healios KK's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLOSF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Healios KK's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Healios KK's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -769.83% mean?
Healios KK (HLOSF) has a Return-on-Tangible-Equity of -769.83% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Healios KK and its competitors. According to the industry distribution chart, Healios KK ranks #999999 out of 1196 companies in the Biotechnology industry.
Is Healios KK's Return-on-Tangible-Equity too high?
Healios KK's current Return-on-Tangible-Equity is -769.83%. Based on the distribution chart, Healios KK ranks #999999 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #999999 out of 1196 companies for Return-on-Tangible-Equity. This places Healios KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Healios KK and its competitors. Healios KK's current Return-on-Tangible-Equity is -769.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.41, compared to a current price of $1.80 — trading 339% above its estimated fair value. The current Return-on-Tangible-Equity is -769.83%. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Healios KK (HLOSF), the current Return-on-Tangible-Equity is -769.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 339% above its estimated GF Value™ of $0.41.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
Return-on-Tangible-Equity: -769.83%
GF Value™: $0.41 vs. price of $1.80 (339% above fair value)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score
Get the complete analysis for HLOSF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
